Background: Basement membrane (BM) genes are an important factor in the process of clear cell renal cell carcinoma (ccRCC). Thus, identifying BMs with prognostic values in ccRCC is critical. Methods: The samples from TCGA were separated randomly into 2 cohorts, the training cohort, and the validation cohort. For the training cohort univariate Cox, Lasso, and multivariate Cox regression analyses were applied to identify prognostic BM genes and then construct a prognostic BM-genes’ signature. The nomogram was applied to predict prognosis at different clinicopathological stages and risk scores. GO and KEGG analyses were applied to the differentially expressed genes. Moreover, the CIBERSORT and ESTIMATE scores were calculated and compared between the high-risk cohort and the low-risk cohort. Results: A prognostic risk model of four BM genes, including ADAMTS14, COL7A1, HSPG2, and TIMP3, was constructed. There were also significant differences in survival time between the high-risk and low-risk groups for the validation cohort and the entire cohort. The risk model was validated as a new independent prognostic factor for ccRCC by univariate and multivariate Cox regression together with clinicopathological characteristics. In addition, a nomogram showed good prediction. The model can also analyze the possibility of immune escape and response to immunotherapy in ccRCC patients. In addition, the results of a pan-cancer analysis showed that these four model genes were associated with immune-related genes in a variety of cancers. Conclusion: The signature of four BM genes had a significant prognostic value for ccRCC. They may be promising targets for therapy, especially immune therapy.
BackgroundProstate cancer (PCa) is a serious threat to the health of elderly aged groups. It is very important to understand the occurrence and development of PCa for early diagnosis, treatment and metastasis control. This study aims to elucidate the international frontier research direction and literature distribution through bibliometric and visual analyses of PCa bone metastasis.MethodsData were obtained from the Web of Science core collection database, which collected 2,246 papers related to PCa bone metastasis from 1 January 2012 to 31 December 2021. The collected data were analyzed using the VOSviewer software for citation, co-authorship, co-citation, bibliometric coupling, and co-occurrence.ResultsOver the past decade, published papers have increased annually. The United States of America has published 890 papers with 29,161 citations, far more than any other country, and it has the most extensive collaboration with other countries. For example, 33 articles by Saad Fred were cited 2,721 times, and 91 articles from the University of Texas MD Anderson CANC CTR were cited 3,037 times, the most cited author and organization. Peng Xinsheng and Duke UNIV comprise the most active collaborative author and organization, respectively. The most co-cited journal was CANCER RES, with 3,195 citations. Studies of PCa bone metastasis can be divided into four categories: “basic research,” “auxiliary diagnosis and treatment,” “clinical trial,” and “prognosis.”ConclusionOur results provide a comprehensive overview of the research priorities and future directions of PCa bone metastasis, which can further accurately guide researchers in diagnosis, treatment, and personalized prevention.
Background: Gene editing tools using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-related systems have revolutionized our understanding of cancer. The purpose of this study was to determine the distribution, collaboration, and direction of cancer research using CRISPR.Methods: Data from the Web of Science (WoS) Core Collection database were collected from 4,408 cancer publications related to CRISPR from 1 January 2013to 31 December 2022. The obtained data were analyzed using VOSviewer software for citation, co-citation, co-authorship, and co-occurrence analysis.Results: The number of annual publications has grown steadily over the past decade worldwide. The United States was shown, by far, to be the leading source of cancer publications, citations, and collaborations involving CRISPR than any other country, followed by China. Li Wei (Jilin University, China), and Harvard Medical School (Boston, MA, United States) were the author and institution with the most publications and active collaborations, respectively. The journal with the most contributions was Nature Communications (n = 147) and the journal with the most citations was Nature (n = 12,111). The research direction of oncogenic molecules, mechanisms, and cancer-related gene editing was indicated based on keyword analysis.Conclusion: The current study has provided a comprehensive overview of cancer research highlights and future trends of CRISPR, combined with a review of CRISPR applications in cancer to summarize and predict research directions and provide guidance to researchers.
Percutaneous nephrolithotomy (PNL) has been used in the treatment of urolithiasis for more than 20 years. However, bibliometric analysis of the global use of PNL for urolithiasis is rare. We retrieved the literatures on PNL and urolithiasis from Web of science core collection database. VOSviewer was used to analyze keywords, citations, publications, co-authorship, themes, and trend topics. A total of 3103 articles were analyzed, most of which were original ones. The most common keywords were “percutaneous nephrology” and “urolithiasis”, both of which were closely related to “ureteroscopy”. Journal of Urology and Zeng Guohua from the First Affiliated Hospital of Guangzhou Medical University were the most published journal and author in this field. The most productive country was the United States, and its closest partners were Canada, China, and Italy. The five hot topics were the specific application methods and means, risk factors of urolithiasis, the development of treatment technology of urolithiasis, the characteristics, composition, and properties of stones, and the evaluation of curative effect. This study aimed to provide a new perspective for PNL treatment of urolithiasis and provided valuable information for urologic researchers to understand their research hotspots, cooperative institutions, and research frontiers.
Background This study aims to conduct the bibliometric and visual analyses in the field of bladder cancer (BC) immunotherapy, and explore the research trends, hotspots and frontiers from 2000 to 2021. Methods Data were obtained from the Web of Science core collection database, which collected 2,022 papers related to BC immunotherapy around the world from 1 January 2000 to 31 December 2021. VOSviewer software was used to comprehensively analyze the collaborative relationships between authors, institutions, countries/regions, journals through citation, co-authorship, co-citation, etc., so as to identify research hotspots and frontiers in this research field. Results The trend of literature publication was relatively flat from 2000 to 2015, and since 2015, the literature publication showed an overall upward trend. The United States of America has published 643 papers with 27,241 citations, ranked first among the top 10 most active countries, and has the most extensive collaboration with other countries. The University of Texas MD Anderson CANC CTR has published 62 articles, making it the most published articles and active collaborative research institution. Kamat AM and Lamm DL were the most active and co-cited authors with 27 papers and 1,039 co-citations, respectively. Chang yuan and Xu le ranked first with 145 total link strength, becoming the most active collaborative authors. J UROLOGY was the most active and frequently co-cited journal, with 106 papers and 6,764 co-citations. Studies of BC immunotherapy can be divided into three categories: “basic research”, “clinical trial” and “prognosis”. Conclusions Our findings provide a comprehensive overview of the research priorities and future directions of BC immunotherapy. Tumor microenvironment and immune checkpoint inhibitors (ICIs) of BC, as well as the combination of ICIs and other drugs may become the main direction of future research.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.